Role of bexarotene in the treatment of cutaneous T-cell lymphoma: The clinical and immunological sides

Immunotherapy

Volumn 5, Issue 4, 2013, Pages 427-433

  Pileri, Alessandro ^a   Delfino, Chiara ^b   Grandi, Vieri ^b   Pimpinelli, Nicola ^b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

bexarotene; cutaneous lymphoma; mycosis fungoides; retinoid; rexinoid

Indexed keywords

BEXAROTENE; ETRETIN; ETRETINATE; FENOFIBRATE; GEMFIBROZIL; ISOTRETINOIN; TRANSCRIPTION FACTOR NFAT;

CANCER INCIDENCE; CELL STRAIN HL 60; CUTANEOUS T CELL LYMPHOMA; DRUG ACTIVITY; DRUG EFFICACY; FOOD AND DRUG ADMINISTRATION; GENE EXPRESSION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; HYPOTHYROIDISM; LEUKOPENIA; LEUKOPENIA;ATE; MYCOSIS FUNGOIDES; PANCREATITIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHOTOCHEMOTHERAPY; PRIORITY JOURNAL; PUVA; REVIEW; SEZARY SYNDROME;

ANTICARCINOGENIC AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; LYMPHOMA, T-CELL, CUTANEOUS; RETINOID X RECEPTORS; TETRAHYDRONAPHTHALENES;

EID: 84875952050     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.13.15     Document Type: Review

References (46)

1. Swerdlow SH, Campo E, Harris NL et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. WHO, Geneva, Switzerland, 270-319 (2008).
2. Bradford PT, Devesa SS, Anderson WF et al. Cutaneous lymphoma incidence patterns in the United States: A population-based study of 3884 cases. Blood 113, 5064-5073 (2009).
3. Weinstock MA, Gardstein B. Twenty-year trends in the reported incidence of mycosis fungoides and associated mortality. Am. J. Public Health 89, 1240-1244 (1999).
4. Olsen E, Vonderheid E, Pimpinelli N et al. Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: A proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 110, 1713-1722 (2007).
5. Willemze R, Jaffe ES, Burg G et al. WHO-EORTC classification for cutaneous lymphomas. Blood 105, 3768-3785 (2005).
6. Trautinger F, Knobler R, Willemze R et al. EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary Syndrome. Eur. J. Cancer 42, 1014-1030 (2006).
7. Gudas LJ, Sporn MB, Roberts AB. Cellular biology and biochemistry of the retinoids. In: The Retinoids (2nd Edition). Sporn MB, Roberts AB, Goodman DS (Eds). Raven Press, NY, USA, 443-520 (1994).
8. Duvic M, Cather JC. Emerging new therapies for cutaneous T-cell lymphoma. Dermatol. Clin. 18, 147-156 (2000).
9. Zackheim HS. Treatment of cutaneous T-cell lymphoma with retinoids. Dermatol. Ther. 8, 15-20 (1998).
10. Zhang C, Duvic M. Treatment of cutaneous T-cell lymphoma with retinoids. Dermatol. Ther. 19, 264-271 (2006).
11. Leverkus M, Rose C, Bröcker EB et al. Follicular cutaneous T-cell lymphoma: Beneficial effect of isotretinoin for persisting cysts and comedones. Br. J. Dermatol. 152, 193-194 (2005).
12. Wargon O, Downie D. A case of mycosis fungoides treated with etretinate. Australas. J. Dermatol. 25, 77-79 (1984).
13. Henney JE. New drug for refractory cutaneous T-cell lymphoma. JAMA 283, 1131 (2000).
14. Duvic M, Martin AG, Kim Y et al. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Arch. Dermatol. 137, 581-593 (2001).
15. Duvic M, Hymes K, Heald P et al. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: Multinational Phase II-III trial results. J. Clin. Oncol. 19, 2456-2471 (2001).
16. Talpur R, Ward S, Apisarnthanarax N et al. Optimizing bexarotene therapy for cutaneous T-cell lymphoma. J. Am. Acad. Dermatol. 47, 672-684 (2002).
17. Whittaker S, Ortiz P, Dummer R et al. Efficacy and safety of bexarotene combined with psoralen-ultraviolet A (PUVA) compared with PUVA treatment alone in stage IB-IIA mycosis fungoides: Final results from the EORTC Cutaneous Lymphoma Task Force Phase III randomized clinical trial (NCT00056056). Br. J. Dermatol. 167, 678-687 (2012).
18. D'Acunto C, Gurioli C, Neri I. Plaque stage mycosis fungoides treated with bexarotene at low dosage and UVB-NB. J. Dermatolog. Treat. 21, 45-48 (2010).
19. Berger E, Altiner A, Chu J et al. Mycosis fungoides stage IB progressing to cutaneous tumors. Dermatol. Online J. 17(10), 5 (2011).
20. Tsirigotis P, Pappa V, Papageorgiou S et al. Extracorporeal photopheresis in combination with bexarotene in the treatment of mycosis fungoides and Sézary syndrome. Br. J. Dermatol. 156, 1379-1381 (2007).
21. Dummer R, Assaf C, Bagot M et al. Maintenance therapy in cutaneous T-cell lymphoma: Who, when, what? Eur. J. Cancer 43, 2321-2329 (2007).
22. Väkevä L, Ranki A, Hahtola S. Ten-year experience of bexarotene therapy for cutaneous T-cell lymphoma in Finland. Acta Derm. Venereol. 92, 258-263 (2012).
23. Abbott RA, Whittaker SJ, Morris SL et al. Bexarotene therapy for mycosis fungoides and Sézary syndrome. Br. J. Dermatol. 160, 1299-1307 (2009).
24. Singh F, Lebwohl MG. Cutaneous T-cell lymphoma treatment using bexarotene and PUVA: A case series. J. Am. Acad. Dermatol. 51, 570-573 (2004).
25. Huber MA, Kunzi-Rapp K, Staib G et al. Management of refractory early-stage cutaneous T-cell lymphoma (mycosis fungoides) with a combination of oral bexarotene and psoralen plus ultraviolet bath therapy. J. Am. Acad. Dermatol. 50, 475-476 (2004).
26. Stadler R. Optimal combination with PUVA: Rationale and clinical trial update. Oncology (Williston Park) 21, 29-32 (2007).
27. Gniadecki R, Assaf C, Bagot M et al. The optimal use of bexarotene in cutaneous T-cell lymphoma. Br. J. Dermatol. 157, 433-440 (2007).
28. Oliveira A, Fernandes I, Alves R et al. Primary cutaneous CD30 positive anaplastic large cell lymphoma - report of a case treated with bexarotene. Leuk. Res. 35, e190-e192 (2011).
29. Mehta N, Wayne AS, Kim YH et al. Bexarotene is active against subcutaneous panniculitis-like T-cell lymphoma in adult and pediatric populations. Clin. Lymphoma Myeloma Leuk. 12, 20-25 (2012).
30. Nagy L, Thomázy VA, Shipley GL et al. Activation of retinoid X receptors induces apoptosis in HL-60 cell lines. Mol. Cell. Biol. 15, 3540-3551 (1995).
31. Kizaki M, Matsushita H, Takayama N et al. Establishment and characterization of a novel acute promyelocytic leukemia cell line (UF-1) with retinoic acid-resistant features. Blood 88, 1824-1833 (1996).
32. Darro F, Cahen P, Vianna A et al. Growth inhibition of human in vitro and mouse in vitro and in vivo mammary tumor models by retinoids in comparison with tamoxifen and the RU-486 anti-progestagen. Breast Cancer Res. Treat. 51, 39-55 (1998).
33. Song JI, Lango MN, Hwang JD et al. Abrogation of transforming growth factoralpha/ epidermal growth factor receptor autocrine signaling by an RXR-selective retinoid (LGD1069, Targretin) in head and neck cancer cell lines. Cancer Res. 61, 5919-5925 (2001).
34. Zhang C, Hazarika P, Ni X, Weidner DA et al. Induction of apoptosis by bexarotene in cutaneous T-cell lymphoma cells: Relevance to mechanism of therapeutic action. Clin. Cancer Res. 8, 1234-1240 (2002).
35. Zoi-Toli O, Vermeer MH, De Vries E et al. Expression of Fas and Fas-ligand in primary cutaneous T-cell lymphoma (CTCL): Association between lack of Fas expression and aggressive types of CTCL. Br. J. Dermatol. 143, 313-319 (2000).
36. Dereure O, Portales P, Clot J, Guilhou JJ. Decreased expression of Fas (APO-1/CD95) on peripheral blood CD4+ T lymphocytes in cutaneous T-cell lymphomas. Br. J. Dermatol. 143, 1205-1210 (2000).
37. Budgin JB, Richardson SK, Newton SB et al. Biological effects of bexarotene in cutaneous T-cell lymphoma. Arch. Dermatol. 141, 315-321 (2005).
38. Richardson SK, Newton SB, Bach TL et al. Bexarotene blunts malignant T-cell chemotaxis in Sèzary syndrome: Reduction of chemokine receptor 4-positive lymphocytes and decreased chemotaxis to thymus and activation-regulated chemokine. Am. J. Hematol. 82, 792-797 (2007).
39. Nieto-Rementería N, Pérez-Yarza G, Boyano MD et al. Bexarotene activates the p53/p73 pathway in human cutaneous T-cell lymphoma. Br. J. Dermatol. 160, 519-526 (2009).
40. Knol AC, Quéreux G, Brocard A et al. Absence of modulation of CD4+CD25 regulatory T cells in CTCL patients treated with bexarotene. Exp. Dermatol. 19, e95-e102 (2010).
41. Knol AC, Quéreux G, Brocard A et al. About the cutaneous targets of bexarotene in CTCL patients. Exp. Dermatol. 19, e299-e301 (2010).
42. Ballanger F, Nguyen JM, Khammari A et al. Evolution of clinical and molecular responses to bexarotene treatment in cutaneous T-cell lymphoma. Dermatology 220, 370-375 (2010).
43. Ranki A, Väkevä L, Sipilä L et al. Molecular markers associated with clinical response to bexarotene therapy in cutaneous T-cell lymphoma. Acta Derm. Venereol. 91, 568-573 (2011).
44. Bagot M, Nikolova M, Schirm-Chabanette F et al. Crosstalk between tumor T lymphocytes and reactive T lymphocytes in cutaneous T cell lymphomas. Ann. NY Acad. Sci. 941, 31-38 (2001).
45. Vermeer MH, van Doorn R, Dukers D et al. CD8+ T cells in cutaneous T-cell lymphoma: Expression of cytotoxic proteins, Fas ligand, and killing inhibitory receptors and their relationship with clinical behavior. J. Clin. Oncol. 19, 4322-4329 (2001).
46. Winter D, Fiebiger E, Meraner P et al. Definition of TCR epitopes for CTLmediated attack of cutaneous T cell lymphoma. J. Immunol. 171, 2714-2724 (2003).